Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2023 Nov 24

PMID 37998814

Authors

Anna Duda-Madej

Szymon Viscardi

Ewa Topola

Affiliations

Soon will be listed here.

Abstract

Due to the fact that there is a steadily increasing trend in the area of antimicrobial resistance in microorganisms, there is a need to look for new treatment alternatives. One of them is the search for new β-lactamase inhibitors and combining them with β-lactam antibiotics, with the aim of increasing the low-dose efficacy, as well as lowering the resistance potential of bacterial strains. This review presents the positive effect of meropenem in combination with a vaborbactam (MER-VAB). This latest antibiotic-inhibitor combination has found particular use in the treatment of infections with the etiology of carbapenem-resistant (CRE), Gram-negative bacteria, with a high degree of resistance to available antimicrobial drugs.

Citing Articles

War and peace: exploring microbial defence systems as a source of new antimicrobial therapies.

Dyson P, Banat I, Quinn G Front Pharmacol. 2025; 15():1504901.

PMID: 39840088 PMC: 11747395. DOI: 10.3389/fphar.2024.1504901.

In Vitro Dynamic Model Evaluation of Meropenem Alone and in Combination with Avibactam Against Carbapenemase-Producing .

Strukova E, Portnoy Y, Golikova M, Zinner S Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770525 PMC: 11678027. DOI: 10.3390/ph17121683.

Prescribing Trends of Fixed-Dose Combination Antibiotics Not Recommended by the WHO (FNRs) for ICU Patients in Six Major Areas of China During a Seven-Year Period.

Zhou L, Zhao Y, Zhu J, Liu J, Liang G, Yang Y Drug Des Devel Ther. 2024; 18:5781-5791.

PMID: 39664964 PMC: 11632048. DOI: 10.2147/DDDT.S493980.

Antibiotic Resistance in the Elderly: Mechanisms, Risk Factors, and Solutions.

Theodorakis N, Feretzakis G, Hitas C, Kreouzi M, Kalantzi S, Spyridaki A Microorganisms. 2024; 12(10).

PMID: 39458286 PMC: 11509523. DOI: 10.3390/microorganisms12101978.

Novel Antibiotics for Gram-Negative Nosocomial Pneumonia.

Almyroudi M, Chang A, Andrianopoulos I, Papathanakos G, Mehta R, Paramythiotou E Antibiotics (Basel). 2024; 13(7).

PMID: 39061311 PMC: 11273951. DOI: 10.3390/antibiotics13070629.

References

Nicolau D . Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis. 2008; 47 Suppl 1:S32-40. DOI: 10.1086/590064. View

Hackel M, Lomovskaya O, Dudley M, Karlowsky J, Sahm D . Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae. Antimicrob Agents Chemother. 2017; 62(1). PMC: 5740317. DOI: 10.1128/AAC.01904-17. View

Tiseo G, Falcone M, Leonildi A, Giordano C, Barnini S, Arcari G . Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 -Producing KPC-31, a D179Y Variant of KPC-3. Open Forum Infect Dis. 2021; 8(6):ofab141. PMC: 8233566. DOI: 10.1093/ofid/ofab141. View

Wunderink R, Giamarellos-Bourboulis E, Rahav G, Mathers A, Bassetti M, Vazquez J . Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. Infect Dis Ther. 2018; 7(4):439-455. PMC: 6249182. DOI: 10.1007/s40121-018-0214-1. View

Gaibani P, Giani T, Bovo F, Lombardo D, Amadesi S, Lazzarotto T . Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing. Antibiotics (Basel). 2022; 11(5). PMC: 9137602. DOI: 10.3390/antibiotics11050628. View

Patel J, Harant A, Fernandes G, Mwamelo A, Hein W, Dekker D . Measuring the global response to antimicrobial resistance, 2020-21: a systematic governance analysis of 114 countries. Lancet Infect Dis. 2023; 23(6):706-718. DOI: 10.1016/S1473-3099(22)00796-4. View

Logan L, Weinstein R . The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace. J Infect Dis. 2017; 215(suppl_1):S28-S36. PMC: 5853342. DOI: 10.1093/infdis/jiw282. View

Wenzler E, Gotfried M, Loutit J, Durso S, Griffith D, Dudley M . Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects. Antimicrob Agents Chemother. 2015; 59(12):7232-9. PMC: 4649232. DOI: 10.1128/AAC.01713-15. View

Yahav D, Giske C, Gramatniece A, Abodakpi H, Tam V, Leibovici L . New β-Lactam-β-Lactamase Inhibitor Combinations. Clin Microbiol Rev. 2020; 34(1). PMC: 7667665. DOI: 10.1128/CMR.00115-20. View

10.

Santoro A, Franceschini E, Meschiari M, Menozzi M, Zona S, Venturelli C . Epidemiology and Risk Factors Associated With Mortality in Consecutive Patients With Bacterial Bloodstream Infection: Impact of MDR and XDR Bacteria. Open Forum Infect Dis. 2020; 7(11):ofaa461. PMC: 7652098. DOI: 10.1093/ofid/ofaa461. View

11.

Theuretzbacher U . Global antimicrobial resistance in Gram-negative pathogens and clinical need. Curr Opin Microbiol. 2017; 39:106-112. DOI: 10.1016/j.mib.2017.10.028. View

12.

Castanheira M, Huband M, Mendes R, Flamm R . Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017; 61(9). PMC: 5571304. DOI: 10.1128/AAC.00567-17. View

13.

Breijyeh Z, Jubeh B, Karaman R . Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It. Molecules. 2020; 25(6). PMC: 7144564. DOI: 10.3390/molecules25061340. View

14.

. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022; 399(10325):629-655. PMC: 8841637. DOI: 10.1016/S0140-6736(21)02724-0. View

15.

Griffith D, Loutit J, Morgan E, Durso S, Dudley M . Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects. Antimicrob Agents Chemother. 2016; 60(10):6326-32. PMC: 5038296. DOI: 10.1128/AAC.00568-16. View

16.

Chen C, Yang K, Peng C, Sheu C, Chan M, Feng J . Clinical outcome of nosocomial pneumonia caused by Carbapenem-resistant gram-negative bacteria in critically ill patients: a multicenter retrospective observational study. Sci Rep. 2022; 12(1):7501. PMC: 9079069. DOI: 10.1038/s41598-022-11061-7. View

17.

Peleg A, Hooper D . Hospital-acquired infections due to gram-negative bacteria. N Engl J Med. 2010; 362(19):1804-13. PMC: 3107499. DOI: 10.1056/NEJMra0904124. View

18.

Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith D . Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017; 61(11). PMC: 5655098. DOI: 10.1128/AAC.01443-17. View

19.

Calo F, Retamar P, Martinez Perez-Crespo P, Lanz-Garcia J, Sousa A, Goikoetxea J . Catheter-related bloodstream infections: predictive factors for Gram-negative bacteria aetiology and 30 day mortality in a multicentre prospective cohort. J Antimicrob Chemother. 2020; 75(10):3056-3061. DOI: 10.1093/jac/dkaa262. View

20.

Alosaimy S, Lagnf A, Morrisette T, Scipione M, Zhao J, Jorgensen S . Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant and . Open Forum Infect Dis. 2021; 8(8):ofab371. PMC: 8378588. DOI: 10.1093/ofid/ofab371. View